Patent Invalidation in Strasbourg.

Patent invalidation Strasbourg strategy runs on a fact that surprises many Alsace companies: no patent case is ever tried in Strasbourg. France centralizes every patent dispute in a single court in Paris, so a BioValley pharma, biotech or chemicals firm defending an assertion on the German border still litigates 490 kilometres away in the capital. What is decided locally is the prior art. Strasbourg sits at the heart of the trinational BioValley life-science cluster spanning Alsace, South Baden and Basel, and the references that anticipate or invalidate its patents live in journal literature, clinical-trial records and EPO files that a routine search never reaches. PerspireIP builds nullity-grade invalidity searches for the pharmaceutical, biotech and chemical companies fighting patents across the Upper Rhine.

Why a patent invalidation Strasbourg case is decided in Paris, not Alsace

France is unusual: it hands every first-instance patent dispute to one court. Under Article L615-17 of the Intellectual Property Code, the Tribunal judiciaire de Paris has exclusive national jurisdiction over patent infringement and nullity actions, a monopoly the Cour de cassation confirmed on 3 March 2015. Cases are heard by the specialised third chamber, split into four sections of three judges, with appeals going to the fifth pole of the Paris Court of Appeal.

For a Strasbourg or wider Grand Est company, that means the venue is fixed the moment a patent is asserted. There is no local Alsace forum, no home-court advantage, and no regional patent track. A nullity action typically reaches a first-instance decision in twelve to eighteen months if the parties hold to the pre-trial calendar.

Because the forum is centralised and specialised, the Paris judges see high-quality prior art constantly. A patent invalidation Strasbourg defence therefore has to arrive in Paris fully charted — references dated to the priority date and mapped element by element — not sketched out during proceedings.

• Exclusive venue — Tribunal judiciaire de Paris under IPC Article L615-17
• Specialised third chamber, four sections of three judges each
• Appeals to the fifth pole of the Paris Court of Appeal
• No local Strasbourg or Grand Est patent forum exists

INPI opposition versus court nullity: two routes to kill a French patent

Since the 2019 PACTE law and implementing Decree No. 2020-225 of 6 March 2020, France finally offers an administrative alternative to litigation. Any third party — except the patent owner — can file a post-grant opposition at INPI, the Institut national de la propriété industrielle, within nine months of the notice of grant, for a fee of €600. It applies only to French patents granted on or after 1 April 2020.

Opposition is lighter and cheaper than a Paris nullity action, with INPI aiming to decide within roughly fifteen to twenty months. But the two tracks interact: an opposition is stayed while a court nullity action on the same patent is pending, and an opponent who loses at INPI may be precluded from later seeking invalidity in court on the same object and the same cause.

Choosing the route is a strategic decision, and both are only as strong as the prior art behind them. Whether you oppose at INPI within the nine-month window or defend a nullity claim in Paris, the search that identifies and dates the anticipating references is the same foundation.

The UPC Central Division in Paris: where BioValley pharma patents land

France was a founding member of the Unified Patent Court, which opened on 1 June 2023, and the seat of its Central Division sits in Paris. That matters directly to Strasbourg, because the Paris seat hears the technical fields that dominate the local economy. Cases are allocated by the IPC classification of the patent.

The Paris Central Division hears patents in IPC section A — ‘Human Necessities’, which includes pharmaceutical preparations (A61K), medical and surgical devices (A61B) and drug-delivery systems (A61M) — along with sections B, D, E, G and H. Critically for the pharma sector, it also hears every case involving a supplementary protection certificate in classes A or C. Chemistry and metallurgy patents in section C go to the Munich seat, while Milan, which opened in 2024, took a share of the former London competences.

• Paris seat — IPC section A (pharma, medical devices) plus B, D, E, G, H, and all SPC cases in classes A or C
• Munich seat — IPC section C, chemistry and metallurgy
• Milan seat — opened 2024, sharing the reallocated former London competences
• A European patent with unitary effect can be revoked centrally across all UPC states in one action

Cross-border enforcement on the German border: the BioValley factor

Strasbourg is a border city, and its life-science economy is deliberately trinational. The BioValley cluster, founded in 1996, links Alsace, South Baden in Germany and northwest Switzerland around Basel — a network of more than 40,000 life-science professionals and branches of Eli Lilly, Pfizer, Sanofi, Novartis and Roche, anchored by the University of Strasbourg’s pharmacology and chemistry base.

That geography multiplies the ways a single patent can be attacked. The same European patent can be enforced in France through the Paris court, in Germany through the national courts or the Nordic-Baltic and German UPC divisions, and centrally through the UPC. A Strasbourg company may therefore face — or launch — parallel proceedings on both sides of the Rhine, where a single strong invalidity file has to work under French, German and UPC standards at once.

For a European patent, there is also the EPO route: any third party can file an opposition at the European Patent Office within nine months of the mention of grant. A coordinated patent invalidation Strasbourg plan often runs an EPO opposition alongside national and UPC challenges, all fed by one prior-art search.

Pharma and biotech invalidity: SPCs, second-medical-use and where prior art hides

Life-science patents fail on grounds that a mechanical search will miss. Supplementary protection certificates extend protection for approved medicines and are frequently attacked on whether the product is ‘protected by a basic patent in force’ and on the certificate’s duration. Second-medical-use claims — a known compound for a new therapeutic indication — turn on whether that use was already disclosed or obvious, and on the plausibility of the claimed effect at the filing date.

The reference that anticipates a pharma or biotech claim rarely sits in a patent database. It lives in peer-reviewed journal articles, conference abstracts, clinical-trial registries and protocols, regulatory dossiers, marketing-authorisation records and university theses. Establishing that such a document was publicly available before the priority date — and reading it onto the claim — is the discipline that decides these cases.

• SPC challenges — basic-patent coverage, product definition and term calculation
• Second-medical-use and dosage-regime claims — novelty, obviousness and plausibility
• Non-patent literature — journals, conference abstracts, clinical-trial records, regulatory files
• Public-availability dating — proving the reference predates the priority date

How PerspireIP builds a patent invalidation Strasbourg search

Every engagement starts the same way: we map the asserted claims element by element, fix the priority date that actually governs each one, and search against that date rather than the filing date on the cover. For BioValley pharma, biotech and chemical subject-matter we run patent and deep non-patent-literature searching in parallel, then build claim charts that a Paris judge, a UPC panel or an INPI opposition division can follow — aligned to the exact grounds you intend to raise.

• Claim charting mapped to French, EPO and UPC invalidity grounds
• Deep literature retrieval across journals, clinical registries and regulatory records
• Public-availability dating for every reference, evidenced and defensible
• Prior art scoped to the nine-month INPI and EPO opposition windows
• Cross-border files built to work in France, Germany and the UPC at once

We work alongside your French and German patent counsel as a specialist search partner, deliver to court, UPC and opposition deadlines, and keep every engagement confidential. Whether you are an Alsace pharmaceutical company defending an SPC, a biotech firm fighting a second-medical-use claim, or a chemicals manufacturer facing a section-C assertion at Munich, we scale to fit — a single search, a multi-patent campaign or ongoing portfolio support. Send us the patent number and your key dates, and we will scope a patent invalidation Strasbourg project within one business day.

IP Landscape & Resources in Strasbourg

Key intellectual-property authorities and venues relevant to Strasbourg:

• INPI (Institut national de la propriété industrielle) — the French patent office that grants French patents and runs the post-grant opposition procedure introduced by the PACTE law
• Tribunal judiciaire de Paris — the court with exclusive national jurisdiction over French patent infringement and nullity actions under IPC Article L615-17
• Unified Patent Court — the UPC, whose Central Division seat in Paris hears pharma and medical-device (IPC section A) and SPC cases for the participating states
• European Patent Office — grants European patents and administers the nine-month post-grant opposition procedure that can revoke a patent centrally

Request a Patent Invalidation Search in Strasbourg

Explore related PerspireIP services: Patent Invalidation · Prior Art Litigation Search · Patent Infringement Analysis.

Frequently Asked Questions